我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

心脏生物标志物临床应用的进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第1期
页码:
123-125,128
栏目:
综述
出版日期:
2010-10-27

文章信息/Info

Title:
-
作者:
刘晓艳; 魏英杰
北京协和医学院阜外心血管病医院再生医学实验室，北京 100037
Author(s):
-
关键词:
心脏; 生物标志物; 肌钙蛋白; 基质金属蛋白酶
Keywords:
-
分类号:
R540.4
DOI:
-
文献标识码:
A
摘要:
心脏生物标志物在临床上的应用已有50多年的历史，它们的作用已不仅仅局限于最初的辅助确诊心肌梗死，而成为多种心脏病诊断的金标准。但现有的标志物还不能满足临床应用的需要，基因组学和蛋白质组学技术的进步推动着心脏生物标志物的发展。本文综述了心脏生物标志物临床应用的进展。
Abstract:
-

参考文献/References

[1]Maisel A. Biomarkers in heart failure. Does prognostic utility translate to clinical futility?[J]. J Am Coll Cardiol, 2007, 50(11):1061-1063.

[2]郭志福，郑兴，秦永文. Ghrelin/Obestain系统与心血管疾病研究进展[J]. 心脏杂志， 2010， 22（1）：123-125.

[3]陈颖敏，徐瑾，李洪波，等. 不同类型冠心病患者血清sCD40L水平及其临床意义[J]. 心脏杂志, 2008, 20(2):213-215.

[4]殷忠，李兰荪，栾荣华，等. 急性冠脉综合征患者PCI术后外周血MMP-9水平的连续观察及其临床意义[J]. 心脏杂志, 2008, 21(1):58-60.

[5]王延风,陈敬州,王曙霞,等. ABCGⅠ启动子区期因多态性与心肌梗死有关联[J]. 心脏杂志, 2008, 20(3):309-312.

[6]Dolci A, Panteghini M. The exciting story of cardiac biomarkers:From retrospective detection to gold diagnostic standard for acute myocardial infarction and more[J] . Clin Chim Acta, 2006, 369(2):179-187.

[7] Setiadi BM, Lei H, Chang J. Troponin not just a simple cardiac marker: prognostic significance of cardiac troponin[J]. Chin Med J, 2009, 122(3):351-358.

[8]Metra M, Nodari S, Parrinello G, et al. The role of plasma biomarkers in acute heart failure.Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T[J]. Eur J Heart Fail, 2007, 9(8):776-786.

[9]Peacock WF IV, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure[J]. N Engl J Med, 2008, 358(20):2117-2126.

[10]Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure[J]. Circulation, 2007, 116(11):1242-1249.

[11]Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)[J]. Eur J Heart Fail, 2008, 10(10):933-989.

[12]Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE trial[J]. J Am CollCardiol, 2007, 50(3):205-214.

[13]王欢，李竹琴，修春红，等. IV-未端脑钠肽原诊断急性心肌梗死患者左室舒张功能的价值及其判断预后的意义[J]. 心脏杂志， 2009， 21（5）：675-677.

[14]Wright G, Struthers A. Natriuretic peptides as a prognostic marker and therapeutic target in heart failure[J]. Heart, 2006, 92(2):149-151.

[15]Talha S, Di marco P, Doutreleau S, et al. Does circulating BNP normalize after heart transp;antation in patients with hemodynamic and right and left heart functions?[J]. Clin Transplant, 2008, 22(5):542-548.

[16]Vaidya VS, Yajnik M, Patel JK, et al. The validity of BNP blood levels to detect heart failure in heart transplant patients[J]. J Heart Lung Transplantati, 2007, 26(2):S120-S121.

[17]Elmas E, Brueckmann M, Lang S, et al. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease[J]. Int J Cardiol, 2008, 128(2):244-249.

[18]von-Haehling S, Jankowska EA, Morgenthaler NG, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-Btype natriuretic peptide in predicting survival in patients with chronic heart failure[J]. J Am Coll Cardiol, 2007, 50(20):1973-1980.

[19]Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study[J]. J Am Coll Cardiol, 2007, 50(7):607-613.

[20]Lassus JP, Harjola VP, Sund R, et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP[J]. Eur Heart J, 2007, 28(15):1841-1847.

[21]Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentia-tion factor-15 in patients with chronic heart failure[J]. J Am Coll Cardiol, 2007, 50(11):1054-1060.

[22]Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes[J]. N Engl J Med, 2008, 358(20):2107-2116.

[23]Bartunek J. Biomarkers: old-new, cardiac-noncardiac, allpaving the way for better stratification in heart failure[J]. Biomarkers Medicine, 2009, 3(5):435-437.

备注/Memo

备注/Memo:
收稿日期：2009-12-17.通讯作者：魏英杰，研究员，主要从事重症心脏病的发病机制和心肌细胞 再生机制的研究Email:weiyingjie@yahoo.com 作者简介：刘晓艳，硕士生Email:lxy-213@163.com
更新日期/Last Update: 2010-10-27